Current treatments and promising investigations in a multidisciplinary setting

Annals of Oncology

Volumn 16, Issue SUPPL. 6, 2005, Pages

  Vokes, E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Cetuximab; Chemoradiotherapy; EGFR; Neoadjuvant; SCCHN; Targeted therapies

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; IMMUNOMODULATING AGENT; METHOTREXATE; MONOCLONAL ANTIBODY ICR 62; MONOCLONAL ANTIBODY R3; PACLITAXEL; PELITINIB; PLATINUM DERIVATIVE; PROTEIN P53; RADIOSENSITIZING AGENT; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HUMAN; HYPERCALCEMIA; METASTASIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; TEAMWORK;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES; PATIENT CARE TEAM; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS;

EID: 27144558304     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi455     Document Type: Article

References (44)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck ancer. N Engl J Med 1993; 328: 184-194.
2. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
3. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
4. Browman GP, Hodson DI, Mackenzie RJ et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck 2001; 23: 579-589.
5. Adelstein DJ, Li Y, Adams Gf, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98.
6. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-2086.
7. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-955.
8. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685-1690.
9. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890-899.
10. Domenge C, Hill C, Lefebvre JL et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Con (GETTEC). Br J Cancer 2000; 83: 1594-1598.
11. Zorat PL, Paccagnella A, Cavaniglia G et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004; 96: 1714-1717.
12. Pignon JP, Syz N, Posner M et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs 2004; 15: 331-340.
13. Vermorken JB, Remenar E, Van Herpen C et al. Standard cisplatin/ infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF JPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (No 14S): Abstr 5508.
14. Vokes EE, Stenson K, Rosen FR et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003; 21: 320-326.
15. Tanigaki Y, Nagashima Y, Kitamura Y et al. The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: Correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. Int J Mol Med 2004; 14: 389-395.
16. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78: 1284-1292.
17. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-7356.
18. Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
19. Kane MA, Cohen EE, List M et al. Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (No 14S): Abstr 5586.
20. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
21. Rhoades CA, Kraut E, Schuller DE et al. Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (No 14S): Abstract 5541.
22. Burtness BA, Li Y, Flood W et al. Phase III randomized trial of cisplatin + placebo versus cisplatin + C225, a monoclonal antibody directed to the epidermal growth factor-receptor: An Eastern Cooperative Oncology Group trial. Clin Cancer Res 2003; 9: Abstr A77.
23. Humblet Y, Vega-Villegas E, Mesia R et al. Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (No 14S): Abstr 5513.
24. Baselga J, Trigo JM, Bourhis J et al. A phase II multicenter study of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2005; in press.
25. Kies MS, Arquette MA, Nabell L et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2002; 21: Abstract 925. Virtual Meeting at www.asco.org.
26. Bonner JA, Giralt J, Harari P et al. Cetuximab prolongs survival in patients with locally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (No 14S): Abstr 5507.
27. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940.
28. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49: 427-433.
29. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637-4642.
30. Milas L, Mason K, Hunter N et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701-708.
31. Nakata E, Hunter N, Mason K et al. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 1163-1173.
32. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-914.
33. Albanell J, Codony-Servat J, Rojo F et al. Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001; 61: 6500-6510.
34. Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101: 567-575.
35. Winquist E, Nabid A, Sicheri D et al. A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc Am Soc Clin Oncol 2002; 21: Abstract 926.
36. Crombet T, Osorio M, Cruz T et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22: 1646-1654.
37. Crombet T, Torres L, Neninger E et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003; 26: 139-148.
38. Hoffmann T, Hafner D, Ballo H et al. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res 1997; 17: 4419-4425.
39. Modjtahedi H, Hickish T, Nicolson M et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 1996; 73: 228-235.
40. Natarajan M, Roldan FA, Sheriff H et al. EKB-569 attenuates radiation triggered survival response in squamous cell carcinom. Proc Am Soc Clin Oncol 2003; 22: Abstract 993.
41. Holsinger FC, Doan DD, Jasser SA et al. Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 2003; 9: 3183-3189.
42. Matar P, Rojo F, Cassia R et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. Clin Cancer Res 2004; 10: 6487-6501.
43. Huang S, Armstrong EA, Benavente S et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64: 5355-5362.
44. Mauer AM, Cohen EE, Wong SJ et al. Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22, No 14S: Abstract 5539.